Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Politics Of Avandia: CDER Memos Reveal Frustration With External Pressure

Executive Summary

FDA internal memos released in connection with the agency’s regulatory decision on GlaxoSmithKline PLC’s Avandia reflect Center for Drug Evaluation and Research officials’ frustration with the spotlight under which they have been operating for the past three years to evaluate rosiglitazone’s cardiovascular risks.

You may also be interested in...



PDUFA Word Association: Consumer Advocates Complain About Lack Of "Safety" In Commitment Letter

FDA’s Oct. 24 public meeting on the renewal of its drug user fee program demonstrated just how strong a position the agency is in regarding the renewal of the Rx part of the “UFA” legislation – most of the complaints were semantic, quite literally.

PDUFA Word Association: Consumer Advocates Complain About Lack Of "Safety" In Commitment Letter

FDA’s Oct. 24 public meeting on the renewal of its drug user fee program demonstrated just how strong a position the agency is in regarding the renewal of the Rx part of the “UFA” legislation – most of the complaints were semantic, quite literally.

FDA Still Most Predictable Part of Drug Development, Despite Bumps, Woodcock Says

Janet Woodcock may take a lot of criticism over problems with FDA’s drug application review and approval process, but she maintains sponsor success at gaining agency approval is better than any other portion of the development process.

Topics

Latest News
UsernamePublicRestriction

Register

PS052687

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel